^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Final progression-free survival analysis of phase II study with the combination therapy of DFP-14323, protease inhibitor, and low-dose afatinib as first-line therapy for common EGFR mutation–positive NSCLC.

Published date:
05/26/2022
Excerpt:
...treatment-naïve patients with common EGFR mutation-positive (L858R/19del) NSCLC were treated with DFP-14323 at a fixed dose of 10mg/day and afatinib...An efficacy analysis provided a DCR of 100% (previously reported) with 18 responders (ORR : 69%)….Combination of DFP-14323 and low-dose afatinib has shown comparable potential as a first-line treatment for EGFR mutation positive NSCLC with feasible efficacy and good safety profile.
DOI:
10.1200/JCO.2022.40.16_suppl.9111
Evidence Level:
Sensitive: C3 – Early Trials
Title:

405P - Promising efficacy as combination therapy of DFP-14323, protease inhibitor, with EGFR-TKI in patients with metastatic NSCLC harboring EGFR mutation

Published date:
11/17/2020
Excerpt:
Stage III/IV and treatment-naïve patients with common EGFR mutation-positive(L858R or 19del) NSCLC were treated with afatinib at a starting dose of 20 mg/day and DFP-14323 at a fixed dose of 10mg/day...Mutation subtypes were half Del-19 and half L858R. DCR was 100% (26/26) with 17 confirmed PRs. Combination of DFP-14323 and low-dose afatinib showed promising efficacy and good tolerability.